Microbiota enterotoxigenic Bacteroides fragilis-secreted BFT-1 promotes breast cancer cell stemness and chemoresistance through its functional receptor NOD1

Abstract

Tumor-resident microbiota in breast cancer promotes cancer initiation and malignant progression. However, targeting microbiota to improve the effects of breast cancer therapy has not been investigated in detail. Here, we evaluated the microbiota composition of breast tumors and found that enterotoxigenic Bacteroides fragilis (ETBF) was highly enriched in the tumors of patients who did not respond to taxane-based neoadjuvant chemotherapy. ETBF, albeit at low biomass, secreted the toxic protein BFT-1 to promote breast cancer cell stemness and chemoresistance. Mechanistic studies showed that BFT-1 directly bound to NOD1 and stabilized NOD1 protein. NOD1 was highly expressed on ALDH⁺ breast cancer stem cells (BCSCs) and cooperated with GAK to phosphorylate NUMB and promote its lysosomal degradation, thereby activating the NOTCH1-HEY1 signaling pathway to increase BCSCs. NOD1 inhibition and ETBF clearance increase the chemosensitivity of breast cancer by impairing BCSCs.

Keywords

microbiota / ETBF / BFT-1 / NOD1 / breast cancer stem cell / chemoresistance

References

[1] Abballe L, Mastronuzzi A, Miele E et al. Numb isoforms deregulation in medulloblastoma and role of p66 isoform in cancer and neural stem cells. Front Pediatr 2018;6:315.

[2] Awad O, Yustein JT, Shah P et al. High ALDH activity identifies chemotherapy-resistant Ewing’s sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLoS One 2010;5:e13943.

[3] Bai N, Liu C, Zhang X et al. NOD1 activation promotes cell apoptosis in papillary thyroid cancer. Pathol Res Pract 2022;233:153880.

[4] Banerjee S, Tian T, Wei Z et al. Distinct microbial signatures associated with different breast cancer types. Front Microbiol. 2018;9:951.

[5] Bessell CA, Isser A, Havel JJ et al. Commensal bacteria stimulate antitumor responses via T cell cross-reactivity. JCI Insight 2020;5:e135597.

[6] Chalabi M, Cardona A, Nagarkar DR et al. imCORE working group of early career investigators. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann Oncol 2020;31:525–531.

[7] Chen GY, Shaw MH, Redondo G et al. The innate immune receptor Nod1 protects the intestine from inflammation-induced tumorigenesis. Cancer Res 2008;68:10060–10067.

[8] Chung L, Thiele Orberg E, Geis AL et al. Bacteroides fragilis toxin coordinates a pro-carcinogenic inflammatory cascade via targeting of colonic epithelial cells. Cell Host Microbe 2018;23:203–214.e205.

[9] Cicalese A, Bonizzi G, Pasi CE et al. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 2009;138:1083–1095.

[10] Cojoc M, Peitzsch C, Kurth I et al. Aldehyde dehydrogenase is regulated by β-Catenin/TCF and promotes radioresistance in prostate cancer progenitor cells. Cancer Res 2015;75:1482–1494.

[11] Derosa L, Routy B, Desilets A et al. Microbiota-centered interventions: The next breakthrough in immuno-oncology? Cancer Discov 2021;11:2396–2412.

[12] Drewes JL, Chen J, Markham NO et al. Human colon cancer-derived Clostridioides difficile strains drive colonic tumorigenesis in mice. Cancer Discov 2022;12:1873–1885.

[13] Fu A, Yao B, Dong T et al. Tumor-resident intracellular micro-biota promotes metastatic colonization in breast cancer. Cell 2022;185:1356–1372.e26 e1326.

[14] Geis AL, Fan H, Wu X et al. Regulatory T-cell response to enterotoxigenic Bacteroides fragilis colonization triggers IL17-dependent colon carcinogenesis. Cancer Discov 2015;5:1098–1109.

[15] Geller LT, Barzily-Rokni M, Danino T et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 2017;357:1156–1160.

[16] Girardin SE, Tournebize R, Mavris M et al. CARD4/Nod1 mediates NF-kappaB and JNK activation by invasive Shigella flexneri. EMBO Rep 2001;2:736–742.

[17] Grajeda-Iglesias C, Durand S, Daillere R et al. Oral administration of Akkermansia muciniphila elevates systemic antiaging and anticancer metabolites. Aging (Albany NY) 2021;13:6375–6405.

[18] Hopkins AM, Kichenadasse G, Karapetis CS et al. Concomitant antibiotic use and survival in urothelial carcinoma treated with Atezolizumab. Eur Urol 2020;78:540–543.

[19] Housseau F, Sears CL. Enterotoxigenic Bacteroides fragilis (ETBF)-mediated colitis in Min (Apc+/−) mice: a human commensal-based murine model of colon carcinogenesis. Cell Cycle (Georgetown, Tex) 2010;9:3–5.

[20] Iida N, Dzutsev A, Stewart CA et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013;342:967–970.

[21] Inohara N, Koseki T, Lin J et al. An induced proximity model for NF-kappa B activation in the Nod1/RICK and RIP signaling pathways. J Biol Chem 2000;275:27823–27831.

[22] Jasemi S, Emaneini M, Ahmadinejad Z et al. Antibiotic resistance pattern of Bacteroides fragilis isolated from clinical and colorectal specimens. Ann Clin Microbiol Antimicrob 2021;20:27.

[23] Jiang HY, Najmeh S, Martel G et al. Activation of the pattern recognition receptor NOD1 augments colon cancer metastasis. Protein & Cell 2020;11:187–201

[24] Kangaba AA, Saglam FY, Tokman HB et al. The prevalence of enterotoxin and antibiotic resistance genes in clinical and intestinal Bacteroides fragilis group isolates in Turkey. Anaerobe 2015;35:72–76.

[25] Keestra-Gounder AM, Tsolis RM. NOD1 and NOD2: beyond peptidoglycan sensing. Trends Immunol 2017;38:758–767.

[26] Kim JM, Cho SJ, Oh YK et al. Nuclear factor-kappa B activation pathway in intestinal epithelial cells is a major regulator of chemokine gene expression and neutrophil migration induced by Bacteroides fragilis enterotoxin. Clin Exp Immunol 2002;130:59–66.

[27] Liu QQ, Li CM, Fu LN et al. Enterotoxigenic Bacteroides fragilis induces the stemness in colorectal cancer via upregulating histone demethylase JMJD2B. Gut Microb 2020;12:1788900.

[28] Ma X, Qiu Y, Zhu L et al. NOD1 inhibits proliferation and enhances response to chemotherapy via suppressing SRC-MAPK pathway in hepatocellular carcinoma. J Mol Med (Berlin, Germany) 2020;98:221–232.

[29] Maisonneuve C, Tsang DKL, Foerster EG et al. Nod1 promotes colorectal carcinogenesis by regulating the immunosuppressive functions of tumor-infiltrating myeloid cells. Cell Rep 2021;34:108677.

[30] Matson V, Fessler J, Bao R et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 2018;359:104–108.

[31] McGill MA, McGlade CJ. Mammalian numb proteins promote Notch1 receptor ubiquitination and degradation of the Notch1 intracellular domain. J Biol Chem 2003;278:23196–23203.

[32] McGill MA, Dho SE, Weinmaster G et al. Numb regulates post-endocytic trafficking and degradation of Notch1. J Biol Chem 2009;284:26427–26438.

[33] Morrison SJ, Kimble J. Asymmetric and symmetric stemcell divisions in development and cancer. Nature 2006;441:1068–1074.

[34] Nejman D, Livyatan I, Fuks G et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science 2020;368:973–980.

[35] Nomoto D, Baba Y, Liu Y et al. Fusobacterium nucleatum promotes esophageal squamous cell carcinoma progression via the NOD1/RIPK2/NF-kappaB pathway. Cancer Lett 2022a;530:59–67.

[36] Nomoto D, Baba Y, Liu Y et al. Fusobacterium nucleatum promotes esophageal squamous cell carcinoma progression via the NOD1/RIPK2/NF-κB pathway. Cancer Lett 2022b;530:59–67.

[37] Parida S, Wu S, Siddharth S et al. A procarcinogenic colon microbe promotes breast tumorigenesis and metastatic progression and concomitantly activates notch and beta-catenin axes. Cancer Discov 2021a;11:1138–1157.

[38] Parida S, Wu S, Siddharth S et al. A procarcinogenic colon microbe promotes breast tumorigenesis and metastatic progression and concomitantly activates notch and β-catenin axes. Cancer Discov 2021b;11:1138–1157.

[39] Park EM, Chelvanambi M, Bhutiani N et al. Targeting the gut and tumor microbiota in cancer. Nat Med 2022;28:690–703.

[40] Pederzoli F, Bandini M, Raggi D et al. Is there a detrimental effect of antibiotic therapy in patients with muscle-invasive bladder cancer treated with neoadjuvant pembrolizumab? Eur Urol 2021;80:319–322.

[41] Plovier H, Everard A, Druart C et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med 2017;23:107–113.

[42] Routy B, Le Chatelier E, Derosa L et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 2018;359:91–97.

[43] Saidi RF, Jaeger K, Montrose MH et al. Bacteroides fragilis toxin rearranges the actin cytoskeleton of HT29/C1 cells without direct proteolysis of actin or decrease in F-actin content. Cell Motil Cytoskeleton 1997;37:159–165.

[44] Saleh L, Wilson C, Holen I. CDK4/6 inhibitors: a potential therapeutic approach for triple negative breast cancer. MedComm 2021;2:514–530.

[45] Sears CL, Pardoll DM. Perspective: alpha-bugs, their microbial partners, and the link to colon cancer. J Infect Dis 2011;203:306–311.

[46] Sepich-Poore GD, Zitvogel L, Straussman R et al. The micro-biome and human cancer. Science (New York, N.Y.) 2021;371:eabc4552.

[47] Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 2011;8:12–23.

[48] Sivan A, Corrales L, Hubert N et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015;350:1084–1089.

[49] Sorensen EB, Conner SD. AAK1 Regulates Numb Function at an Early Step in Clathrin-Mediated Endocytosis. Traffic 2008;9:1791.

[50] Sóki J, Wybo I, Hajdú E et al; ESCMID Study Group on Anaerobic Infections. A Europe-wide assessment of antibiotic resistance rates in bacteroides and parabacteroides isolates from intestinal microbiota of healthy subjects. Anaerobe 2020a;62:102182.

[51] Sóki J, Wybo I, Hajdú E et al; ESCMID Study Group on Anaerobic Infections. A Europe-wide assessment of antibiotic resistance rates in bacteroides and parabacteroides isolates from intestinal microbiota of healthy subjects. Anaerobe 2020b;62:102182.

[52] Thiele Orberg E, Fan H, Tam AJ et al. The myeloid immune signature of enterotoxigenic Bacteroides fragilis-induced murine colon tumorigenesis. Mucosal Immunol 2017;10: 421–433.

[53] Urbán E, Horváth Z, Sóki J et al. First Hungarian case of an infection caused by multidrug-resistant Bacteroides fragilis strain. Anaerobe 2015;31:55–58.

[54] Urbaniak C, Gloor GB, Brackstone M et al. The microbiota of breast tissue and its association with breast cancer. Appl Environ Microbiol. 2016;82:5039–5048.

[55] Viaud S, Saccheri F, Mignot G et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013;342:971–976.

[56] Wu S, Lim KC, Huang J et al. Bacteroides fragilis enterotoxin cleaves the zonula adherens protein, E-cadherin. Proc Natl Acad Sci U S A 1998;95:14979–14984.

[57] Wu S, Powell J, Mathioudakis N et al. Bacteroides fragilis enterotoxin induces intestinal epithelial cell secretion of interleukin- 8 through mitogen-activated protein kinases and a tyrosine kinase-regulated nuclear factor-kappaB pathway. Infect Immun 2004;72:5832–5839.

[58] Yu T, Guo F, Yu Y et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell 2017;170:548–563.e16.

[59] Zhang W, Wang Y. Activation of RIPK2-mediated NOD1 signaling promotes proliferation and invasion of ovarian cancer cells via NF-κB pathway. Histochem Cell Biol 2022;157:173–182.

RIGHTS & PERMISSIONS

2024 The Author(s) 2024. Published by Oxford University Press on behalf of Higher Education Press.